Flow Cytometry Market Hits US$10.3B by 2032: Why Every Lab Needs a FACS Flow Cytometer?
Delray Beach, FL, June 13, 2025 (GLOBE NEWSWIRE) — Ever wondered how scientists peek inside our cells, analyzing their secrets to diagnose diseases or develop life-saving therapies? It's all thanks to flow cytometry, a dynamic field transforming healthcare and research. And at its core, the remarkable FACS flow cytometer market leads the charge, offering unparalleled precision in analyzing and sorting cells.
Imagine a sophisticated, high-speed sorting machine for microscopic cells. That's essentially what a flow cytometer machine does, and the FACS flow cytometer excels, providing meticulous insights into everything from cell cycle flow to identifying disease-causing biomarkers.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65374584
This market is exploding, projected to jump from US$5.1 billion in 2024 to US$10.3 billion by 2032, growing at a robust 9.2% CAGR. What's fueling this surge? Rapid technological advancements (especially in FACS flow cytometer systems), increasing adoption in clinical diagnostics, rising chronic disease rates, booming biopharmaceutical R&D, and the urgent demand for precision medicine. Even AI and machine learning are boosting data analysis, accelerating this growth.
Why the Buzz? Opportunities & Challenges in Flow Cytometry
The global flow cytometry market offers exciting opportunities, but it's not without hurdles:
Drivers: Innovation Pushes Boundaries
The market thrives on new, advanced flow cytometry products and flow cytometer machines. Manufacturers are focused on creating instruments that are powerful, user-friendly, and incredibly fast. A cutting-edge FACS flow cytometer can analyze and sort thousands of cells per second with unmatched accuracy. Recent innovations like multiplexing, higher throughput systems, and smarter data analysis software are making these tools indispensable.
Case in point: In April 2024, Becton, Dickinson and Company launched the BD FACSDiscover S8 Cell Sorter. This advanced spectral cell sorter, a prime FACS flow cytometer, combines real-time imaging with spectral analysis—a game-changer for detailed cellular purification.
Restraints: The Cost Barrier
Despite the benefits, high costs pose a challenge. Labs often require many flow cytometry instruments, leading to significant capital and maintenance expenses. For academic & research laboratories with restricted budgets, affording a high-end FACS flow cytometer can be tough. A single flow cytometer machine can cost over USD 500,000, and FACS flow cytometer-based cell sorters are typically pricier than cell analyzers due to their precision. This cost can slow adoption, especially in emerging countries.
Opportunities: Expanding Clinical Horizons
Increased use in clinical applications and infectious disease diagnostics is a massive opportunity. A cell cytometer, particularly a precise FACS flow cytometer, is invaluable for disease diagnosis, prognosis, and monitoring. In hematology, it's key for leukemia and lymphoma diagnosis, identifying rare cancer cells. In immunology, it helps diagnose immunodeficiencies and autoimmune disorders.
Example: In March 2024, Beckman Coulter's DxFLEX Clinical Flow Cytometer received USFDA clearance, validated for 10-color immunophenotyping for leukemia and lymphoma—a clear win for clinical FACS flow cytometer applications.
Challenges: Reagent Complexity
Complexities related to reagent development present a notable challenge. These reagents (like fluorescently labeled antibodies and dyes) are vital for any flow cytometer machine, including FACS flow cytometer systems. Creating high-quality, specific, and stable reagents is time-consuming and resource-intensive, requiring extensive testing to ensure accurate, reproducible results across diverse applications.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=65374584
Who's Driving Growth? Market Segments & Global Leaders Reagents & Consumables: This segment dominated the flow cytometry market in 2023 , essential for any flow cytometer machine , especially advanced FACS flow cytometer systems.
This segment dominated the , essential for any , especially advanced systems. Academic & Research Institutes: Poised for substantial growth, driven by increased investment in clinical trials, drug development, and a demand for high-throughput FACS flow cytometer capabilities.
Poised for substantial growth, driven by increased investment in clinical trials, drug development, and a demand for high-throughput capabilities. North America: Led the global flow cytometry market in 2023 due to robust healthcare infrastructure, significant investment in research and development, and high adoption of advanced flow cytometry technologies. The Asia Pacific region is expected to show significant growth.
Key market players like Becton, Dickinson and Company (US), Danaher Corporation (US), and Thermo Fisher Scientific Inc. (US) are continuously innovating, often focusing on new FACS flow cytometer models to strengthen their market position.
Recent Developments: From Agilent's NovoCyte Opteon Spectral Flow Cytometer (May 2024) to Sony's FP7000 spectral cell sorter (October 2023) and BD's groundbreaking FACSDiscover S8 Cell Sorter (March 2023), these innovations highlight the rapid evolution of FACS flow cytometer technology.
FAQs Shaping Industry Conversations:
1. What is the core purpose of a Flow Cytometer machine?
A flow cytometer machine rapidly analyzes and sorts microscopic cells in fluid, using lasers to gather data on cell size, granularity, and specific markers via scattered light and fluorescence. Essential for both fundamental research and precise disease diagnosis.
2. How does a FACS Flow Cytometer elevate cellular analysis?
A FACS flow cytometer goes beyond analysis. As an advanced cell cytometer, it physically separates and collects specific cell populations based on their characteristics. This allows for high-purity isolation of rare cells, crucial for in-depth research and therapeutic development.
3. Why is the global flow cytometry market experiencing such explosive growth?
The global flow cytometry market is booming, projected to reach US$10.3 billion by 2032, driven by tech advancements (e.g., spectral analysis in FACS flow cytometer), rising adoption in clinical diagnostics, increasing chronic disease prevalence, and surging biopharmaceutical R&D. AI and machine learning further accelerate this expansion.
4. What are the key hurdles in adopting flow cytometry instruments?
The main challenge is the high cost of instruments, often exceeding USD 500,000, especially for advanced FACS flow cytometer models. Complexities in reagent development also add to the operational cost, limiting adoption for smaller academic & research laboratories with restricted budgets.
5. How critical is flow cytometry in understanding cell cycle flow and diagnosing blood cancers?
Flow cytometry is vital for studying cell cycle flow by analyzing cellular DNA content. Clinically, a FACS flow cytometer is indispensable for diagnosing hematological malignancies like leukemia and lymphoma, by precisely identifying and characterizing abnormal immune cell populations based on unique surface markers.
For more information, Inquire Now!
Related Reports:
Single Cell Analysis Market
Cell Based Assays Market
Esoteric Testing Market
Research Antibodies Market
Cell Analysis Market
Get access to the latest updates on Top Companies in Flow Cytometry and Flow Cytometry Market Size
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
an hour ago
- Business Upturn
OGN FRAUD ALERT: Organon & Co. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 22 Legal Deadline (NYSE:OGN)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting Investors have until July 22, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Organon securities. The case is pending in the U.S. District Court for the District of New Jersey and is captioned: Hauser v. Organon & Co., et al. , No. 25-cv-05322. Why was Organon Sued for Securities Fraud? Organon is a global healthcare company focused on women's health that has historically rewarded its shareholders with a healthy dividend. In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company focused on dermatological conditions. As alleged, while the acquisition increased Organon's debt, the Company assured investors it would maintain its dividend, which Organon asserted was its '#1 capital allocation priority.' In truth, Organon had shifted its capital allocation priority after the Dermavant acquisition to focus on reducing its debt, ultimately leading the Company to severely cut its dividend. The Stock Declines as the Truth is Revealed On May 1, 2025, Organon announced that management reset the Company's dividend payout from $0.28 per share to $0.02 per share. Organon's CEO explained that the Company 'reset our capital allocation priorities to accelerate progress towards deleveraging' and that '[b]y deleveraging more rapidly, we will continue to strengthen the future prospects of the company.' Organon's CFO added, '[t]he biggest issues we face . . . relate to managing our leverage and relate to growth. And we need capital to solve both of those issues, and so returning capital to shareholders is right now, less of a priority.' On this news, the price of Organon stock declined roughly 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025. Click here if you suffered losses: What Can You Do? If you invested in Organon you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
an hour ago
- Business Upturn
IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
an hour ago
- Business Upturn
AIXA Miner Integrates AI and Clean Energy to Power a New Era of Cloud Mining in 2025
Denver, CO, USA, June 22, 2025 (GLOBE NEWSWIRE) — In a major advancement for the global crypto mining industry, AIXA Miner today announced the expansion of its AI-powered cloud mining platform, now fully supported by green energy sources. The move strengthens AIXA Miner's position as a forward-thinking player in the digital asset space, while making daily crypto income more accessible and more sustainable for users worldwide. As interest in decentralized finance grows and regulatory focus sharpens, 2025 is proving to be a pivotal year for crypto mining. AIXA Miner's cloud-based system offers a hardware-free, AI-optimized, and environmentally conscious mining solution that requires no prior technical knowledge or large capital investment. Bridging Crypto, AI, and Sustainability Designed for beginners and experienced users alike, AIXA Miner enables anyone to start earning daily rewards in leading cryptocurrencies — including Bitcoin, Ethereum, and Litecoin — through its intelligent, cloud-hosted mining architecture. The platform's unique value lies in its combination of: Artificial intelligence , used to dynamically allocate mining resources for optimal output , used to dynamically allocate mining resources for optimal output Clean energy-powered mining farms , cutting environmental impact , cutting environmental impact Free sign-up mining trial , giving newcomers a risk-free entry point , giving newcomers a risk-free entry point Low-cost mining contracts , with flexible durations and terms , with flexible durations and terms Daily payouts and full earnings control, accessible via a secure user dashboard In line with the industry's green transition, AIXA's energy-efficient infrastructure operates in regions with abundant renewable energy sources, aligning with broader ESG standards and carbon neutrality goals. Making Daily Crypto Income Simple AIXA Miner's goal is to eliminate complexity from crypto mining. Users simply register with an email, choose a mining plan (or start with the free trial), and the platform's backend takes care of everything — from resource allocation to performance tracking. With 24/7 cloud uptime, earnings accumulate automatically, and users can withdraw or reinvest anytime. This 'plug-and-earn' experience reflects a growing demand for low-risk, passive income solutions that don't rely on expensive hardware or volatile trading environments. Start Mining in Minutes Go to Register with your email to activate your free trial Choose the crypto you want to mine Let the AI-powered engine begin mining Monitor your earnings in real-time Withdraw anytime, or grow your income with longer-term plans Building a Smarter Mining Future AIXA Miner's 2025 expansion is not just about mining more coins — it's about doing so responsibly, intelligently, and inclusively. With built-in support for multiple global languages and secure wallet integrations, the platform is tailored for a worldwide user base seeking transparent, stable, and eco-friendly mining solutions. About AIXA Miner Founded in 2020, AIXA Miner is a U.S.-based cloud mining platform powered by renewable energy and artificial intelligence. With a presence in over 200 countries and regulatory certifications, the platform delivers secure, daily-yield mining services that are easy to access and designed for long-term sustainability. For more information, visit: [ Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
